Clinical Trials Directory

Trials / Conditions / Refractory Transformed Chronic Lymphocytic Leukemia

Refractory Transformed Chronic Lymphocytic Leukemia

12 registered clinical trials studyying Refractory Transformed Chronic Lymphocytic Leukemia — 8 currently recruiting.

StatusTrialSponsorPhase
RecruitingAnti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Re
NCT07166419
Ohio State University Comprehensive Cancer CenterPhase 1
RecruitingZanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation
NCT06735664
City of Hope Medical CenterPhase 1
TerminatedGenetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19
NCT06343376
Roswell Park Cancer InstitutePhase 1
WithdrawnVenetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From
NCT06247540
Northwestern UniversityPhase 2
RecruitingB-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cycloph
NCT06191887
Mayo ClinicPhase 1
RecruitingLoncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymp
NCT05672251
City of Hope Medical CenterPhase 2
RecruitingZanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome
NCT05873712
Aseel AlsouqiPhase 2
RecruitingLisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation
NCT05672173
City of Hope Medical CenterPhase 2
RecruitingCD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
NCT04892277
Mayo ClinicPhase 1
RecruitingGenetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lym
NCT05418088
Sumithira VasuPhase 1
Active Not RecruitingA Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Exp
NCT03277729
Fred Hutchinson Cancer CenterPhase 1 / Phase 2
Active Not RecruitingAtezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymph
NCT02846623
M.D. Anderson Cancer CenterPhase 2